Tundo A, et al. - In unipolar and bipolar depression, researchers examined the efficacy and safety of pramipexole via this systematic review including five randomized clinical trials, three open label trials and five observational studies including 504 participants. The participants were 57% women with a mean age of 45.3 years. In this study, some evidence supporting the efficacy of pramipexole for the treatment of major depressive episodes were gained. It had an overall short-term response rate of 52.2% and a remission rate of 36.1%; also, an overall long-term response rate of 62.1% and remission rate of 39.6% were reported with good acceptability and tolerability. Nausea was identified to be the most frequent side effect.